

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF POWER OF ATTORNEY, NEW POWER OF
ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


INTERMUNE INC., the owner of the entire right, title and interest in the attached listing of U.S. patent applications (Schedule A), hereby revokes all Powers of Attorney previously given in such patent applications. INTERMUNE INC. is the Assignee of the entire right and interest in each of these U.S. patent applications, as evidenced by the documentary evidence of the chain of title from the original owner to the Assignee, recorded in the Assignment records of the office at the reel/frame numbers indicated on Schedule A.

INTERMUNE INC. hereby appoints the attorneys and/or agents associated with customer number 89229 to prosecute these patent applications and transact all business in the U.S. Patent and Trademark Office.

Please recognize and change the correspondence address for the patent applications listed in Schedule A to the address associated with customer number 89229:

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300

INTERMUNE INC.


Name: John Bendrick

Title: Vice President, Intellectual Property, InterMune, Inc.

Date: March 2, 2010

Schedule A

US Patent Applications			Title		Reel/Frame
MGB Reference	Application Number	Filing or 371 (c) Date			
30481/30042	60/327,743	10/5/2001	Methods of treating liver fibrosis and hepatitis C virus infection		013214/0400
30481/30044	60/460,194	4/4/2003	Compositions and methods for treating viral infections		014749/0016
30481/30038	60/471,404	5/16/2003	Hybrid chemokine receptor ligands and methods of use thereof		014480/0790
30481/30046	60/471,841	5/16/2003	Combination IFN therapy		015175/0822
30481/30046A	60/485,474	7/8/2003	Combination IFN therapy for proliferative disorders		015175/0822
30481/30046B	60/511,415	10/14/2003	Interferon-gamma and TNF-alpha antagonist combination therapy for the treatment of fibrotic diseases		015451/0312
30481/30046C	60/511,280	10/14/2003	Combination therapy for the treatment of fibrotic diseases		014488/0659
30481/30046D	60/511,259	10/14/2003	Combination therapy for the treatment of fibrotic diseases		015531/0013
30481/30046E	60/514,173	10/24/2003	Combination therapy for treating proliferative disorders		014295/0659
30481/30047	60/511,169	10/14/2003	Combination therapy for the treatment of viral diseases		014282/0107
30481/30046F	60/561,940	4/13/2004	Combination therapy for the treatment of fibrotic diseases		014986/0522
30481/30048	60/579,625	6/14/2004	Interferon compositions and methods of use thereof		015241/0447
30481/30042A	10/490,457	8/16/2004	Methods of treating liver fibrosis and hepatitis c virus infection		015818/0726
30481/30040	60/660,074	3/8/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections		016089/0180
30481/30050	60/668,631	4/5/2005	Method of treating alphavirus infection		017138/0709
30481/30039	60/682,544	5/18/2005	Non-natural chemokine receptor ligands and methods of use thereof		018174/0953
30481/30048A	11/153,864	6/14/2005	Interferon compositions and methods of use thereof		016804/0339
30481/30040P	60/707,891	8/12/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections		017593/0867
30481/30043B	10/545,631	8/12/2005	Interferon drug therapy for the treatment of viral diseases and liver fibrosis		016997/0081
30481/30044A	10/552,020	10/3/2005	Compositions and methods for treating viral infections		016799/0876
30481/30046G	10/555,390	11/2/2005	Combination therapy for proliferative disorders		014986/0522
30481/30049A	11/356,634	2/17/2006	Biomarkers for predicting liver fibrosis treatment efficacy		017645/0626

US Patent Applications				
MGB Reference	Application Number	Filing or 371 (c) Date	Title	Reel/Frame
30481/30038A	10/555,735	11/30/2006	Synthetic chemokine receptor ligands and methods of use thereof	014480/0790
30481/30041	60/983,854	10/30/2007	HCV Genotyping and phenotyping assays	020838/0721
30481/30041P	61/043,020	4/7/2008	HCV Genotyping and phenotyping	020838/0721
30481/30039A	11/913,768	5/23/2008	Non-natural chemokine receptor ligands and methods of use thereof	018174/0953 022218/0835
30481/30041A	12/262,111	10/30/2008	HCV Genotyping and phenotyping	022323/0487
30481/30040B	12/617,676	11/12/2009	Use of alpha-glucosidase inhibitors to treat alphavirus infections	023698/0792

US Patents						
MGB Reference	Application Number	Filing or 371(c) Date	Patent No.	Issue Date	Title	Reel/Frame
30481/30037A	09/529,303	4/12/2000	6,455,051	9/24/2002	Ameriorant for hepatitis C therapeutic effect and application thereof	010805/0564
30481/30040A	11/370,535	3/7/2006	7,638,488	12/29/2009	Use of alpha-glucosidase inhibitors to treat alphavirus infections	017758/0555